title: Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification.
abstract: OBJECTIVE
  To evaluate the results of radiotherapy in patients with primary cutaneous B-cell lymphoma (CBCL) classified according to the criteria of the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification.
  
  
  METHODS
  Multicenter, 20-year, retrospective, cohort analysis.
  
  
  METHODS
  Eight dermatology departments collaborating in the Dutch Cutaneous Lymphoma Group.
  
  
  METHODS
  From 1985 until 2005, a total of 153 patients with CBCL were initially treated with radiotherapy with curative intent. These cases were classified according to the WHO-EORTC classification and consisted of 25 primary cutaneous marginal zone lymphomas (PCMZLs), 101 primary cutaneous follicle center lymphomas (PCFCLs), and 27 primary cutaneous large B-cell lymphomas, leg type (PCLBCLs, LT). Interventions Local radiotherapy with a median dose of 40 Gy (range, 20-46 Gy) applied to all visible skin lesions.
  
  
  METHODS
  Complete remission rate, relapse rate, 5-year relapse-free survival, 5-year overall survival, and 5-year disease-specific survival.
  
  
  RESULTS
  Complete remission was reached in 151 of 153 patients (99%). Relapse rates for PCMZL, PCFCL, and PCLBCL, LT were 60%, 29%, and 64%, and the 5-year disease-specific survival was 95%, 97%, and 59%, respectively. The PCFCLs presenting on the legs had a higher relapse rate (63%) and a much lower 5-year disease-specific survival (44%) than PCFCLs at other sites (relapse rate, 25%; 5-year disease-specific survival, 99%).
  
  
  CONCLUSIONS
  Radiotherapy is a suitable treatment for a large group of patients with CBCL. However, patients with PCFCL presenting with lesions on the leg and patients with PCLBCL, LT display a more unfavorable clinical course and should therefore be treated with more aggressive treatment modalities.
authors: Department of Dermatology, B1-Q, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. N.J.Senff@LUMC.nl
authors: Nancy J
authors: NJ
authors: Senff
authors: Juliette J
authors: JJ
authors: Hoefnagel
authors: Karen J
authors: KJ
authors: Neelis
authors: Maarten H
authors: MH
authors: Vermeer
authors: Ed M
authors: EM
authors: Noordijk
authors: Rein
authors: R
authors: Willemze
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D005260:Female; D006801:Humans; D015994:Incidence; D008223:Lymphoma / Q000145:classification / Q000532:radiotherapy; D016393:Lymphoma, B-Cell / Q000145:classification* / Q000532:radiotherapy*; D008224:Lymphoma, Follicular / Q000145:classification / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D012074:Remission Induction; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000145:classification* / Q000532:radiotherapy*; D016019:Survival Analysis; D014944:World Health Organization